Take note: Presentation
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
JUNE 01, 2024
Poster Details:
Abstract Title:“Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma”
Abstract Title:“Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma”
Abstract #:9561
Poster Bd #:345
Track:Melanoma/Skin Cancers
Location:Hall A – McCormick Place
Date/Time:Saturday, June 1, 1:30 – 4:30 p.m.
CDTPresenter:Mads Lausen Nielsen, Senior Scientist
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1030Followers
64Following
6963Visitors
Follow